OR WAIT null SECS
January 21, 2020
The agreement centers around the development of new stem-cell derived allogeneic T-cell therapies for the treatment of cancer.
GE Healthcare Life Sciences’ new facility for cell and gene processing supplies will be open in 2022.
January 16, 2020
The next-generation gene editing system can be applied to the development of novel cell and gene therapies.
January 15, 2020
ProBioGen and Lava Therapeutics have closed the cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate.
December 06, 2019
The new software lets users choose the volume and cell concentration from initial cell preparation through transduction to final resuspension, without compromising cell viability and virus stability.
December 05, 2019
The new 50,000-square-foot facility will create 200 new jobs and accelerate commercialization of gene and cell therapies.
December 02, 2019
Aiming to break the bottlenecks that are slowing commercialization of innovative therapies, a new $50-million center in Boston will develop both cell and viral vector products within a single facility.
November 25, 2019
Biopharma company, Zelluna Immunotherapy, and clinical stage biotech, Glycostem Therapeutics, have entered into a partnership focused on the development and manufacture of allogeneic T-cell receptor guided Natural Killer cell therapies for the treatment of cancer.
November 21, 2019
Lonza and Cryoport have partnered up to strengthen Lonza’s ‘vein-to-vein’ delivery network by removing supply chain hurdles faced by developers of personalized therapeutics.
November 01, 2019
A number of experts will be examining investment opportunities within the evolving cell and gene therapy sector, in a panel discussion on Wednesday morning (Nov. 6, 2019) during CPhI Worldwide in Frankfurt, Germany.